FDA Approves Shionogi's Oral Antiviral Ensitrelvir for COVID-19 Postexposure Prophylaxis
By
Terrence Rudd
1mo ago· 2 min readenNews
Summary
The FDA has approved ensitrelvir (Xocova), an oral antiviral developed by Shionogi, for preventing COVID-19 in people aged 12 and older who have been exposed to SARS-CoV-2. The drug, which is a main protease inhibitor, was already approved in Japan for postexposure prophylaxis. Clinical data showed that ensitrelvir reduced the risk of developing COVID-19 among household contacts by more than half.
Source
bskyFDA Approves Shionogi's Oral Antiviral Ensitrelvir for COVID-19 Postexposure Prophylaxismedpagetoday.comKey quotes
· 3 pulledThe FDA approved the oral antiviral agent ensitrelvir (Xocova) to help prevent COVID-19 in people ages 12 years or older who were exposed to the SARS-CoV-2 virus, drugmaker Shionogi announced.
Ensitrelvir is a SARS-CoV-2 main protease inhibitor also approved in Japan as COVID-19 postexposure prophylaxis (PEP)
Ensitrelvir cut household contacts' risk of developing COVID by more than half
Ensitrelvir cut household contacts' risk of developing COVID by more than half
You might also wanna read
FDA Approves First 100% Effective HIV Prevention Drug with Global Impact
The article discusses the milestone approval of the first HIV prevention drug, lenacapavir (brand name Yeztugo), which offers 100% protectio
newatlas.com·11mo ago
SARS-CoV-2 RBD nanoparticle vaccine shows potent neutralization against variants in clinical studies
This article describes the characterization of a two-component protein nanoparticle vaccine platform (RBD-NP) that displays 60 copies of the
pmc.ncbi.nlm.nih.gov·11d ago
BREAKING: HHS Terminates the COVID-19 Emergency Use Authorization Declarations Covering mRNA Shots, Drugs, and Biologics
Courageous Discourse·7d ago
Fiscalização da Vigilância Sanitária apreende medicamentos no Rio de Janeiro
agenciabrasil.ebc.com.br·6y ago
Acre defende atuação de médicos formados no exterior durante pandemia de Covid 19
agenciabrasil.ebc.com.br·6y ago
Elecsys Anti-SARS-CoV-2 S im Labor: Welche Vorteile und Grenzen der Roche-Serologie hat
IT BOLTWISE·6h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.